红霉素链霉菌聚酮合成酶基因eryAIII的克隆及其在大肠杆菌中的表达

目的:在大肠杆菌中异源表达红霉素链霉菌聚酮合成酶eryAIII基因。方法:构建表达载体pET-m28a,PCR扩增高GC含量长片段基因eryAIII及分子伴侣GroELS的基因,并插入该载体,每个基因都能够独立启动和终止表达;将重组质粒转化至大肠杆菌BL21(DE3),用IPTG进行诱导表达。结果:NdeⅠ、HindⅢ分别酶切质粒pET-m28a/eryAIII-GroELS,琼脂糖凝胶电泳显示获得与预期大小相同的DNA片段;SDS-PAGE结果表明,重组大肠杆菌表达了由eryAIII编码的相对分子质量为348×103的蛋白;与GroELS共表达后,目的蛋白在上清中的表达量明显增加。结论:GroELS提高了eryAIII编码蛋白的可溶性,为红霉素合成通路在大肠杆菌中的重建奠定了基础。     

红霉素链霉菌聚酮合成酶基因eryA Ⅲ的克隆及其在大肠杆菌中的表达

目的:在大肠杆菌中异源表达红霉素链霉菌聚酮合成酶eryA Ⅲ基因.方法:构建表达载体pET-m28a,PCR扩增高GC含量长片段基因eryA Ⅲ及分子伴侣GroELS的基因,并插入该载体,每个基因都能够独立启动和终止表达;将重组质粒转化至大肠杆菌BL21(DE3),用IPTG进行诱导表达.结果:NdeⅠ、Hind Ⅲ分别酶切质粒pET-m28a/eryA Ⅲ-GroELS,琼脂糖凝胶电泳显示获得与预期大小相同的DNA片段;SDS-PAGE结果表明,重组大肠杆菌表达了由eryA Ⅲ编码的相对分子质量为348×103的蛋白;与GroELS共表达后,目的蛋白在上清中的表达量明显增加.结论:GroELS提高了eryA Ⅲ编码蛋白的可溶性,为红霉素合成通路在大肠杆菌中的重建奠定了基础.     

猪繁殖与呼吸综合征病毒M+N基因重组腺病毒载体的构建

本研究构建了M+N基因的重组腺病毒载体。首先用反转录聚合酶链反应(RT-PCR)的方法分别扩增出猪繁殖与呼吸综合征病毒M基因和N基因,将两者用口蹄疫病毒2A序列串联起来,将连接好的M+N基因插入腺病毒穿梭载体pAdTrack-CMV,经筛选获得了重组质粒pAdTrack-CMV/M+N;然后在大肠杆菌BJ5183内将此重组质粒和腺病毒骨架载体pAdEasy-1进行同源重组,获得了插有外源基因的重组腺病毒质粒pAd/M+N;最后,经PacⅠ酶切线性化后转染HEK-293细胞,成功获得含有M+N基因的重组腺病毒,为重组腺病毒活载体疫苗的研究奠定基础。     

一种多基因串联共表达载体的构建

为了构建一种可用于串联共表达多个基因的原核表达载体,通过PCR引入点突变,对商业载体pET-22b的酶切位点进行定向改造,设计独特的XbaⅠ/SpeⅠ模块。获得改造成功的载体pET-m22b,测序结果显示启动子、核糖体结合位点、多克隆位点及终止子均位于XbaⅠ和SpeⅠ两酶切位点间。选取不同来源的基因进行串联组合及表达鉴定,四个基因成功组合于同一载体中,表达效果良好,各基因表达效率不受明显影响。研究构建的载体pET-m22b,使多基因的共表达更加便捷,为蛋白复合物的表达与纯化、代谢通路的异源重建及其优化等研究奠定了良好的基础。     

以thyA基因为选择压力非抗性质粒载体的构建

以干酷乳杆菌L.casei34103染色体DNA为模板,利用PCR技术扩增胸苷酸合成酶（Thymidylatesynthase,thyA)基因,回收纯化,选择以红霉素抗性为选择压力的可以在大肠杆菌和乳酸菌中穿梭表达的质粒pW425e为基本质粒,以thyA基因取代红霉素基因,获得重组载体并鉴定,此重组载体可以对thyA基因缺陷的大肠杆菌E.coli X51和嗜酸乳杆菌DOMLaS 107进行功能弥补,进而构建了以thyA基因为地选择压力的非抗生素抗性穿梭表达载体,其大小为3716bp,并命名为pW425t。     

基因工程技术合成一种新的酮内酯类化合物3—去氧—3—羰基—红霉内酯B

大环内酯类抗生素基因工程是近年来生物工程领域研究的一个热点 ,利用基因工程改造大环内酯类抗生素合成基因 ,已经合成了 10 0多种“非天然”的天然化合物 ,为筛选新抗生素开辟了新的途径。本研究以糖多孢红霉菌Ａ2 2 6基因组ＤＮＡ为模板 ,先用ＰＣＲ扩增出红霉素合成基因ｅｒｙＫＲ6两侧片段 ,再用重叠ＰＣＲ将其拼接成去除ＫＲ6的约 3.2ｋｂＤＮＡ片段 ,并克隆于ｐＷＨＭ3载体 ,构建了同源重组质粒ｐＷＨＭ2 2 0 1。用ＰＥＧ介导将ｐＷＨＭ2 2 0 1转入糖多孢红霉菌Ａ2 2 6原生质体。ＰＣＲ鉴定和生物活性检测均显示ｐＷＨＭ2 2 0 1已重…     

邻苯二酚氧化酶基因在根癌农杆菌中的表达——多用途基因载体的构建

来源于假单胞杆菌的邻苯二酚氧化酶结构基因与质粒四环素抗性基因的启动子相拼接构成的融合基因,不仅能在大肠杆菌中表达,而且也能在根癌农杆菌中表达。带有这融合基因作为标记的重组质粒pBZ 731,具有EcoR Ⅰ,Hind Ⅲ,BamH Ⅰ,Kpn Ⅰ,Hpa Ⅰ等多个单一的酶切位点,因而可作为常规的基因载体。重组质粒pBZ 732还可作为中间载体将外源基因引入植物基因工程载体pGV 3850,利用pBZ731和pBZ 732可以研究任何其它来源的启动子是否能在根癌农杆菌中发挥作用。以pBZ731和pBZ 732作为基因载体、检测方便而且极其迅速。     

抗冻蛋白结构基因片段的克隆

为了研究和开发利用抗冻蛋白或多肽,木文通过聚合酶链式反应（ＰＣＲ）合成了抗冻蛋白１１０ｂｐ的结构基因片段,然后将该基因片段克隆到大肠杆菌质粒载体Ｐ（Ｂｌｕｅｓｃｒｉｐｔ）Ⅱｋｓ＋／－上,获得了重组质粒,经酶切证明,获得的重组质粒中含有抗冻蛋白结构基因片段,以供该基因在大肠杆菌或酵母中表达抗冻蛋白。     

猪繁殖与呼吸综合症病毒E基因克隆及重组腺病毒表达载体的构建

研究采用RT-PCR技术对猪繁殖与呼吸综合症病毒(PRRSV)E基因进行了克隆、测序和特征分析,得到长度为603 bp,编码201个氨基酸残基的目的基因片段.将克隆到的E基因插入到pAdTrack-CMV穿梭质粒中,再将重组穿梭质粒pAdTrack-CMV/E用PmeⅠ线性化后电转化携带有腺病毒骨架载体pAdeasy-1的大肠杆菌BJ5183感受态细胞,经细菌内同源重组产生重组腺病毒质粒pAdEasy-E,成功获得了含有PRRSV E基因的重组腺病毒表达载体.为猪繁殖与呼吸综合症活载体疫苗的研制提供了依据.     

重组靶向核糖体失活蛋白luffin-α-NGR的制备及抗肿瘤活性评价

将丝瓜籽核糖体失活蛋白luffin-α与肿瘤靶向肽NGR融合,制备luffin-α-NGR重组蛋白,并检测其对肿瘤细胞与血管生成的抑制活性.通过引物设计及PCR扩增获得luffin-α-NGR融合基因,与pGEX-6p-1载体连接后获得pGEX-6p-1/luffin-α-NGR重组质粒,质粒转入大肠杆菌(Escher...     

6-deoxyerythronolide B production through chromosomal localization of the deoxyerythronolide B synthase genes in E. coli

Chromosomal engineering was used to localize the deoxyerythronolide B synthase (DEBS) genes and propionyl-CoA carboxylase (PCC) genes to the BAP1 Escherichia coli chromosome creating the new strain YW9. YW9 then featured a plasmid-free heterologous pathway for the production of the polyketide product 6-deoxyerythronolide B (6dEB, a precursor to the antibiotic erythromycin) highlighted by the successful chromosomal integration of five genes total and three DEBS genes each approximately 10 kb in length. The new strain was tested for small-scale 6dEB biosynthesis and compared to 6dEB production from plasmid-derived gene expression at 22, 30, and 37 degrees C. YW9 produced 6dEB at each temperature tested; whereas, the current plasmid-based system could only produce 6dEB at 22 and 30 degrees C. As determined by MS analysis, average production levels for YW9 were 0.47 (22 degrees C), 0.52 (30 degrees C), and 0.11 (37 degrees C)mg/L.     

Production of the potent antibacterial polyketide erythromycin C in Escherichia coli

An Escherichia coli strain capable of producing the potent antibiotic erythromycin C (Ery C) was developed by expressing 17 new heterologous genes in a 6-deoxyerythronolide B (6dEB) producer strain. The megalomicin gene cluster was used as the source for the construction of two artificial operons that contained the genes encoding the deoxysugar biosynthetic and tailoring enzymes necessary to convert 6dEB to Ery C. The reconstructed mycarose operon contained the seven genes coding for the enzymes that convert glucose-1-phosphate (G-1-P) to TDP-L-mycarose, a 6dEB mycarosyl transferase, and a 6dEB 6-hydroxylase. The activity of the pathway was confirmed by demonstrating conversion of exogenous 6dEB to 3-O-alpha-mycarosylerythronolide B (MEB). The reconstructed desosamine operon contained the six genes necessary to convert TDP-4-keto-6-deoxyglucose, an intermediate formed in the mycarose pathway, to TDP-D-desosamine, a desosamine transferase, a 6dEB 12-hydroxylase, and the rRNA methyltransferase ErmE; the last was required to confer resistance to the host cell upon production of mature macrolide antibiotics. The activity of this pathway was demonstrated by conversion of MEB to Ery C. When the mycarose and desosamine operons were expressed in an E. coli strain engineered to synthesize 6dEB, Ery C and Ery D were produced. The successful production of Ery C in E. coli shows the potentiality of this model microorganism to synthesize novel 6-deoxysugars and to produce bioactive glycosylated compounds and also establishes the basis for the future use of E. coli both in the production of new glycosylated polyketides and for the generation of novel bioactive compounds through combinatorial biosynthesis.     

Analysis of the maximum theoretical yield for the synthesis of erythromycin precursors in Escherichia coli

The heterologous biosynthesis of complex polyketides in Escherichia coli was recently achieved through metabolic engineering. However, it was observed that less than 10% of the propionate carbon source is transformed into the erythromycin precursor, 6-deoxyerythronolide B (6dEB), resulting in a 1.4% molar yield. Therefore, metabolic flux analysis was performed using a model of the Escherichia coli metabolism with the addition of the enzymes required for 6dEB synthesis. The analysis shows that the maximum theoretical yield for 6dEB synthesis in E. coli is 11%. The maintenance energy requirement of E. coli and limitations in the specific oxygen uptake rate can further decrease the yield, suggesting that the observed 6dEB yield of 1.4% can be the result of these two factors. In addition, the results suggest that an increase in the specific carbon and oxygen uptake rates will increase the yield of 6dEB. The use of glucose as an alternative carbon source was also evaluated using metabolic flux analysis and the results suggest that the choice of glucose as the carbon source will allow a small improvement in performance relative to a propionate-based process.     

Improved E. coli erythromycin A production through the application of metabolic and bioprocess engineering

In this report, small-scale culture and bioreactor experiments were used to compare and improve the heterologous production of the antibiotic erythromycin A across a series of engineered prototype Escherichia coli strains. The original strain, termed BAP1(pBPJW130, pBPJW144, pHZT1, pHZT2, pHZT4, pGro7), was designed to allow full erythromycin A biosynthesis from the exogenous addition of propionate. This strain was then compared against two alternatives hypothesized to increase final product titer. Strain TB3(pBPJW130, pBPJW144, pHZT1, pHZT2, pHZT4, pGro7) is a derivative of BAP1 designed to increase biosynthetic pathway carbon flow as a result of a ygfH deletion; whereas, strain TB3(pBPJW130, pBPJW144, pHZT1, pHZT2, pHZT4-2, pGro7) provided an extra copy of a key deoxysugar glycosyltransferase gene. Production was compared across the three strains with TB3(pBPJW130, pBPJW144, pHZT1, pHZT2, pHZT4, pGro7) showing significant improvement in erythronolide B (EB), 3-mycarosylerythronolide B (MEB), and erythromycin A titers. This strain was further tested in the context of batch bioreactor production experiments with time-course titers leveling at 4 mg/L, representing an approximately sevenfold increase in final erythromycin A titer.     

Process and metabolic strategies for improved production of Escherichia coli-derived 6-deoxyerythronolide B

Recently, the feasibility of using Escherichia coli for the heterologous biosynthesis of complex polyketides has been demonstrated. In this report, the development of a robust high-cell-density fed-batch procedure for the efficient production of complex polyketides is described. The effects of various physiological conditions on the productivity and titers of 6-deoxyerythronolide B (6dEB; the macrocyclic core of the antibiotic erythromycin) in recombinant cultures of E. coli were studied in shake flask cultures. The resulting data were used as a foundation to develop a high-cell-density fermentation procedure by building upon procedures reported earlier for recombinant protein production in E. coli. The fermentation strategy employed consistently produced approximately 100 mg of 6dEB per liter, whereas shake flask conditions generated between 1 and 10 mg per liter. The utility of an accessory thioesterase (TEII from Saccharopolyspora erythraea) for enhancing the productivity of 6dEB in E. coli was also demonstrated (increasing the final titer of 6dEB to 180 mg per liter). In addition to reinforcing the potential for using E. coli as a heterologous host for wild-type- and engineered-polyketide biosynthesis, the procedures described in this study may be useful for the production of secondary metabolites that are difficult to access by other routes.     

Metabolic engineering of<Emphasis Type="Italic"> Escherichia coli</Emphasis> for improved 6-deoxyerythronolide B production

Escherichia coli is an attractive candidate as a host for polyketide production and has been engineered to produce the erythromycin precursor polyketide 6-deoxyerythronolide B (6dEB). In order to identify and optimize parameters that affect polyketide production in engineered E. coli, we first investigated the supply of the extender unit (2S)-methylmalonyl-CoA via three independent pathways. Expression of the Streptomyces coelicolor malonyl/methylmalonyl-CoA ligase (matB) pathway in E. coli together with methylmalonate feeding resulted in the accumulation of intracellular methylmalonyl-CoA to as much as 90% of the acyl-CoA pool. Surprisingly, the methylmalonyl-CoA generated from the matB pathway was not converted into 6dEB. In strains expressing either the S. coelicolor propionyl-CoA carboxylase (PCC) pathway or the Propionibacteria shermanii methylmalonyl-CoA mutase/epimerase pathway, methylmalonyl-CoA accumulated up to 30% of the total acyl-CoA pools, and 6dEB was produced; titers were fivefold higher when strains contained the PCC pathway rather than the mutase pathway. When the PCC and mutase pathways were expressed simultaneously, the PCC pathway predominated, as indicated by greater flux of ¹³C-propionate into 6dEB through the PCC pathway. To further optimize the E. coli production strain, we improved 6dEB titers by integrating the PCC and mutase pathways into the E. coli chromosome and by expressing the 6-deoxyerythronolide B synthase (DEBS) genes from a stable plasmid system.S. Murli and J. Kennedy contributed equally to this work     

Cloning of DNA sequences encoding foreign peptides and their expression in the K88 pili

A genetic system that allows the cloning of a peptide-coding sequence in the Escherichia coli K88ac and K88ad pilin genes and their expression as recombinant pili has been constructed. Two insertion vectors were created by subcloning the pilin genes in a pBR322 plasmid and replacing the coding sequence of two nonconserved clusters by a linker. The K88ac helper genes were subcloned in the compatible pACYC184 plasmid, and expression of pili by bacteria carrying both plasmids occurred by complementation. Two peptide-coding sequences of the influenza hemagglutinin were cloned in both insertion vectors, and recombinant pilins were shown to be assembled in pili. One recombinant pilus was shown to elicit antibodies against the synthetic peptide in immunized rats. The somatostatin-coding sequence was cloned in both vectors and led in one case to detectable pilus production. The fused somatostatin was shown to be recognized by specific monoclonal and polyclonal antibodies.     

Cloning of DNA sequences encoding foreign peptides and their expression in the K88 pili.

A genetic system that allows the cloning of a peptide-coding sequence in the Escherichia coli K88ac and K88ad pilin genes and their expression as recombinant pili has been constructed. Two insertion vectors were created by subcloning the pilin genes in a pBR322 plasmid and replacing the coding sequence of two nonconserved clusters by a linker. The K88ac helper genes were subcloned in the compatible pACYC184 plasmid, and expression of pili by bacteria carrying both plasmids occurred by complementation. Two peptide-coding sequences of the influenza hemagglutinin were cloned in both insertion vectors, and recombinant pilins were shown to be assembled in pili. One recombinant pilus was shown to elicit antibodies against the synthetic peptide in immunized rats. The somatostatin-coding sequence was cloned in both vectors and led in one case to detectable pilus production. The fused somatostatin was shown to be recognized by specific monoclonal and polyclonal antibodies.     

含苏氨酸操纵子重组质粒的构建及其对大肠杆菌L-苏氨酸积累的影响

摘要：【目的】通过分子生物学手段构建重组质粒,将其转入野生型大肠杆菌W3110,分析含苏氨酸操纵子基因的质粒及质粒定点突变解除反馈抑制时,对L-苏氨酸积累的影响。【方法】以W3110染色体DNA为模板,PCR扩增苏氨酸操纵子基因,即启动子THrLp、编码前导肽基因thrL以及thrA、thrB、thrC基因,通过重叠延伸PCR的方法对thrA基因定点突变,解除苏氨酸对它的反馈抑制,构建出重组表达质粒WYE112和WYE134,5 L发酵实验测定L-苏氨酸的产量。【结果】经5 L发酵罐发酵产酸实验,W3110的L-苏氨酸产量为0.036 ± 0.004 g/L,携带含苏氨酸操纵子质粒的W3110菌株L-苏氨酸产量为2.590 ± 0.115 g/L,质粒上thrA解除反馈抑制后,L-苏氨酸的产量增加到9.223 ± 1.279 g/L。【结论】过表达苏氨酸操纵子基因可以使L-苏氨酸积累,进一步解除thrA基因的反馈抑制,可以增强L-苏氨酸积累的效果,为L-苏氨酸工程菌改造的进一步研究奠定了基础。     

Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon

This study reports the development of several cloning vectors for bifidobacteria based on the replicon of pBC1, a cryptic plasmid from Bifidobacterium catenulatum L48 thought to replicate via the theta mode. These vectors, in which antibiotic resistance genes encoding either erythromycin or tetracycline resistance acted as selection markers, were able to replicate in a series of eight Bifidobacterium species at frequencies ranging from 4.0 x 10(1) to 1.0 x 10(5) transformants microg(-1) but not in Lactococcus lactis or Lactobacillus casei. They showed a relative copy number of around 30 molecules per chromosome equivalent and a good segregational stability, with more than 95% of the cells retaining the vectors after 80 to 100 generations in the absence of selection. Vectors contain multiple cloning sites of different lengths, and the lacZalpha peptide gene was introduced into one of the molecules, thus allowing the easy selection of colonies harboring recombinant plasmids in Escherichia coli. The functionality of the vectors for engineering Bifidobacterium strains was assessed by cloning and examining the expression of an alpha-l-arabinofuranosidase gene belonging to Bifidobacterium longum. E. coli and Bifidobacterium pseudocatenulatum recombinant clones were stable and showed an increase in alpha-arabinofuranosidase activity of over 100-fold compared to that of the untransformed hosts.